Cargando…
Seven‐day vonoprazan‐based triple therapy as first‐line Helicobacter pylori treatment in comparison with extended sequential therapy
BACKGROUND AND AIM: Vonoprazan as a new acid blocker has more potency and longer lasting acid suppression than proton pump inhibitors. Whether the efficacy of vonoprazan‐based triple therapy is comparable with or even better than that of currently recommended first‐line therapies is still unknown. O...
Autores principales: | Chiu, Yu‐Tse, Lee, Fu‐Jen, Kuo, Chen‐Ya, Lin, Yang‐Chao, Liang, Kai‐Shun, Tseng, Liang‐Wei, Chen, Yu‐Tsung, Chang, Chi‐Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Publishing Asia Pty Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958340/ https://www.ncbi.nlm.nih.gov/pubmed/36852150 http://dx.doi.org/10.1002/jgh3.12858 |
Ejemplares similares
-
The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of Helicobacter pylori
por: Zhang, Zinan, et al.
Publicado: (2023) -
Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication
por: Kusunoki, Maho, et al.
Publicado: (2019) -
Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
por: Sugimoto, Mitsushige, et al.
Publicado: (2019) -
The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy
por: Miftahussurur, Muhammad, et al.
Publicado: (2020) -
Safety and effectiveness of vonoprazan-based rescue therapy for Helicobacter pylori infection
por: Yu, Jing, et al.
Publicado: (2023)